clinical trial · NCT02367456
A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients
Pfizer·phase1·completed·n = 73
Myelodysplastic SyndromeAcute Myeloid LeukemiaChronic Myelomonocytic LeukemiaPF-04449913 (Glasdegib)Azacitidine
brief summary
This multi center open label Phase 1b study is designed to evaluate the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of glasdegib (PF-04449913) when combined with azacitidine in patients with previously untreated Higher Risk Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML). This clinical study includes two components: (a) a safety lead in cohort (LIC) and (b) an expansion phase with an AML cohort and an MDS cohort.
started
Apr 28, 2015
primary completion
Jan 29, 2020
completion
Mar 7, 2022
last updated
Jan 19, 2024
official title
An Open-label Phase 1b Study of PF-04449913 (Glasdegib) in Combination With Azacitidine in Patients With Previously Untreated Higher-Risk Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol